查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1830376

合成激素市场（按激素类别、应用、技术和最终用户划分）—2025-2032 年全球预测

Synthetic Hormones Market by Hormone Class, Application, Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年合成荷尔蒙市场规模将成长至 31.1 亿美元，复合年增长率为 14.89%。

主要市场统计数据
基准年2024年 10.2亿美元
预计2025年 11.7亿美元
预测年份：2032年 31.1亿美元
复合年增长率（%） 14.89%

合成激素领域的权威概况，重点介绍临床驱动因素、技术进步以及产业相关人员的策略要务

合成激素领域正处于临床需求、技术创新和不断变化的监管格局的交汇点。近期趋势表明，合成胜肽及其类似物正在加速发展，同时人们也更加重视安全性、便捷的给药方式和价格承受能力。随着远端医疗和居家医疗的兴起，病患就医路径也随之演变，製造商和医疗保健提供者必须在复杂的生产需求、严格的品管和竞争激烈的价格压力之间取得平衡。

重组DNA技术和复杂化学合成的转化医学进展，使得治疗方法种类更加丰富，但也带来了新的生产依赖和监管触点。同时，人口结构趋势、不断发展的临床指南以及患者对微创给药的偏好，正在重塑避孕、糖尿病、生长激素缺乏症、更年期和甲状腺疾病的临床实践模式。这些动态要求相关人员重新思考其产品组合策略、生产布局和通路互动模式。

对于寻求将科学进步转化为持续商业性成果的组织而言，清晰的策略至关重要。本报告提炼了最重要的变革，识别了基于细分领域的影响，并提出了切实可行的建议，以帮助企业在掌握科学和市场发展势头的同时规避营运风险。

对重塑荷尔蒙疗法发展途径和商业策略的技术、监管和管道变化的引人注目的分析

过去十年，合成荷尔蒙的开发、生产和输送方式发生了翻天覆地的变化。重组DNA方法和细胞表现系统的创新拓展了治疗分子的可行范围，使生技药品的纯度更高，批次间性能更稳定。同时，製剂科学和输送装置的进步降低了自我给药的门槛，将荷尔蒙疗法的覆盖范围从传统的临床环境扩展到居家医疗和远端医疗模式。

管理体制日益精细，围绕生物相似药对比策略和激素类药物长期使用的药物药物安全检测审查日益严格。这些监管变化促使人们更加重视临床证据的产生和上市后安全监测，进而影响研发进度和商业性定位。同时，供应链的韧性也变得至关重要，製造商正在实现原材料供应商的地域多元化，并投资于冗余产能，以缓解地缘政治和物流中断的影响。

数位药局和以处方笺为基础的线上配药平台正在改变患者获取和依从性模式，而专科诊所和综合医疗服务提供者正在尝试订阅模式和捆绑式医疗服务。总而言之，这些变化要求产业参与者调整其研发、监管策略、製造投资和商业模式，以保持成长并应对新兴风险。

深入检验2025 年关税如何迫使整个合成激素价值链进行供应链重组、采购多样化和定价策略

2025年累积关税的实施对合成荷尔蒙生态系统的成本结构、供应商选择和策略采购产生了重大影响。依赖跨境供应链的製造商面临新的激励机制，需要重新评估其供应商组合，在可行的情况下优先考虑在地采购，并重新协商长期奖励，以吸收或缓解关税相关的成本压力。此类调整通常需要重新调整筹资策略，以支援在优惠贸易区内营运的供应商，并探索近岸外包选项，以降低进口关税和物流波动带来的风险。

製药公司还必须权衡迁移某些生产流程与维持供应连续性之间的营运利弊。对一些製药公司而言，虽然资本密集型，但事实证明，为确保关键中间体和生技药品的产量，采用先进的生产流程具有战略意义。在其他情况下，投资双源框架和库存缓衝提供了更大的灵活性，以适应关税波动。同时，付款人和经销商已开始更密切地审查定价和报销动态，这促使一些製造商加快成本效益计划，并追求强调医疗总成本而非仅仅单位成本的价值证明。

整体而言，关税环境凸显了综合商业和供应链策略的必要性，这种策略可以抵御政策主导的衝击，同时保持不同医疗环境中荷尔蒙疗法的可及性和品质。

综合細項分析，将荷尔蒙类别、治疗用途、实行技术和最终用户管道与可操作的策略重点连结起来

深入的细分能够明确治疗和商业机会所在，以及营运风险集中。根据荷尔蒙类别，市场涵盖雌激素、胰岛素和甲状腺，每种激素代表不同的临床路径和生产方式，需要量身定制的监管策略和给药方法。根据应用，市场涵盖避孕、糖尿病、生长激素缺乏症、更年期和甲状腺疾病；避孕涵盖口服复方避孕药和纯孕激素避孕药；生长激素缺乏症涵盖成人和儿童生长激素缺乏症；更年期症状涵盖潮热、骨质疏鬆症和阴道萎缩；甲状腺疾病涵盖甲状腺功能亢进和甲状腺机能低下症和甲状腺机能低下症和甲状腺功能低下。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 使用生物合成雌二醇和睪固酮类似物的个人化荷尔蒙补充疗法的激增
  • 透过整合人工智慧主导的分子设计加速新型合成胜肽激素的发现
  • 监管部门的核准推动了合成 GnRH 类似物的长效缓释製剂的采用
  • 增加对植物来源生物合成途径的投资，实现永续的黄体素生产
  • 扩展具有超快速作用特性的合成胰岛素类似物，以实现精确的血糖控制
  • 渗透性促进剂和奈米载体开发口服合成胜肽激素
  • 远端医疗医疗处方平台的成长正在推动对家用荷尔蒙疗法套件的需求
  • 製药公司和生物技术公司之间的策略合作，以扩大化学酶激素合成
  • 合成人体生长荷尔蒙持续皮下输送系统的开发
  • 市场转向实验室培养的微生物发酵途径，以实现经济高效的 hGH 生产

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 合成荷尔蒙市场荷尔蒙类别

  • 雌激素
  • 胰岛素
  • 甲状腺

9. 合成荷尔蒙市场（依应用）

  • 避孕
    • 复方口服避孕药
    • 仅含黄体素的避孕药
  • 糖尿病
  • 生长激素缺乏症
    • 成人生长激素缺乏症
    • 儿童生长激素缺乏症
  • 更年期症状
    • 热潮红
    • 骨质疏鬆症
    • 阴道萎缩
  • 甲状腺疾病
    • 甲状腺功能亢进
    • 甲状腺机能低下症

10. 合成荷尔蒙市场（依技术）

  • 化学合成
    • 液相合成
    • 固相合成
  • 重组DNA技术
    • 细菌表现系统
    • 哺乳动物细胞表现系统
    • 酵母表现系统

第 11 章。 合成激素市场（按最终用户）

  • 诊所
    • 综合诊所
    • 专科诊所
  • 居家照护环境
    • 护理服务
    • 自我管理
  • 医院
    • 私立医院
    • 公立医院
  • 网路药局
    • 在商店
    • 处方笺
  • 零售药局
    • 连锁药局
    • 独立药房

第 12 章。按地区分類的合成荷尔蒙市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 合成荷尔蒙市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章 各国合成荷尔蒙市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Pfizer Inc.
    • Johnson & Johnson
    • AbbVie Inc.
    • Bristol Myers Squibb Company
    • Sanofi SA
    • AstraZeneca PLC
    • Novo Nordisk A/S
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Ferring BV
    • Endo Pharmaceuticals Inc.
    • Lupin Pharmaceuticals Inc.
    • IBSA Institute Biochimique SA
Product Code: MRR-431C35F6C25D

The Synthetic Hormones Market is projected to grow by USD 3.11 billion at a CAGR of 14.89% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.02 billion
Estimated Year [2025] USD 1.17 billion
Forecast Year [2032] USD 3.11 billion
CAGR (%) 14.89%

An authoritative overview of the synthetic hormones landscape highlighting clinical drivers, technological advances, and strategic imperatives for industry stakeholders

The synthetic hormones landscape sits at the intersection of clinical need, technological innovation, and shifting regulatory frameworks. Recent years have witnessed accelerated development of engineered peptides and analogs alongside renewed emphasis on safety, delivery convenience, and affordability. As patient pathways evolve through expanded telehealth adoption and greater home-based care, manufacturers and healthcare providers must reconcile complex production demands with stringent quality controls and competitive pricing pressures.

Translational progress in recombinant DNA techniques and refined chemical synthesis has enabled a broader therapeutic palette, but it also introduces new manufacturing dependencies and regulatory touchpoints. Concurrently, clinical practice patterns for contraception, diabetes, growth hormone deficiency, menopausal care, and thyroid disorders are being reshaped by demographic trends, evolving clinical guidelines, and patient preferences for less invasive administration. These dynamics require stakeholders to rethink portfolio strategies, manufacturing footprints, and channel engagement models.

Strategic clarity is now essential for organizations that seek to convert scientific advances into durable commercial outcomes. This report distills the most consequential shifts, identifies segmentation-driven implications, and offers actionable recommendations to navigate operational risks while capturing momentum from scientific and market developments.

Compelling analysis of converging technological, regulatory, and channel shifts that are reshaping development pathways and commercial strategies for hormone therapies

The past decade has brought transformative shifts that are redefining how synthetic hormones are developed, manufactured, and delivered. Innovations in recombinant DNA methods and cell expression systems have expanded the feasible range of therapeutic molecules, enabling higher purity biologics and more consistent batch-to-batch performance. At the same time, advances in formulation science and delivery devices have reduced barriers to self-administration, thereby extending the reach of hormone therapies beyond traditional clinical settings into homecare and telemedicine-facilitated models.

Regulatory regimes are becoming more nuanced, with agencies intensifying scrutiny on comparator strategies for biosimilars and on pharmacovigilance for long-term hormone use. This regulatory tightening is fostering greater emphasis on clinical evidence generation and post-market safety surveillance, which in turn influences development timelines and commercial positioning. Concurrently, supply chain resilience has moved to the forefront, with manufacturers seeking geographic diversification of raw material suppliers and investing in redundant manufacturing capacities to mitigate geopolitical and logistic disruptions.

Market channels are also shifting: digital pharmacies and prescription-based online dispensing platforms are altering patient acquisition and adherence patterns, while specialty clinics and integrated care providers are experimenting with subscription models and bundled care pathways. Taken together, these shifts demand that industry participants align R&D, regulatory strategy, manufacturing investments, and commercial models to sustain growth and manage emerging risks.

In-depth examination of how 2025 tariff measures have compelled supply chain reconfiguration, sourcing diversification, and pricing strategies across the synthetic hormones value chain

The implementation of cumulative tariffs in 2025 has had material implications for cost structures, supplier selection, and strategic sourcing within the synthetic hormones ecosystem. Manufacturers that rely on cross-border supply chains faced renewed incentives to reassess their vendor portfolios, prioritize local content where feasible, and renegotiate long-term agreements to absorb or mitigate tariff-related cost pressures. These adjustments often entailed reconfiguring procurement strategies to favor suppliers operating within preferential trade zones or exploring nearshoring options to reduce exposure to import duties and logistical volatility.

Pharmaceutical companies also had to weigh the operational trade-offs between relocating certain production steps and maintaining continuity of supply. For some, re-shoring advanced manufacturing processes proved capital intensive but strategically justified to secure critical intermediates and biologics output. For others, investing in dual-sourcing frameworks and inventory buffering provided a more flexible response to tariff volatility. In parallel, payers and distributors scrutinized price and reimbursement dynamics more closely, prompting some manufacturers to accelerate cost-efficiency programs and to pursue value demonstrations that emphasize total cost of care rather than unit price alone.

Overall, the tariff environment highlighted the need for integrated commercial and supply chain strategies that can withstand policy-driven shocks while preserving access and quality of hormone therapies across diverse care settings.

Comprehensive segmentation analysis that links hormone classes, therapeutic applications, enabling technologies, and end-user channels to actionable strategic priorities

Insight-driven segmentation clarifies where therapeutic and commercial opportunities converge and where operational risks concentrate. Based on hormone class, the market is studied across Estrogen, Insulin, and Thyroid, each representing distinct clinical pathways and manufacturing modalities that require tailored regulatory strategies and delivery approaches. Based on application, the market is studied across Contraception, Diabetes, Growth Hormone Deficiency, Menopausal Symptoms, and Thyroid Disorders; within this dimension, Contraception is further studied across Combined Oral Contraceptive and Progestin Only Contraceptive, Growth Hormone Deficiency is further studied across Adult GHD and Pediatric GHD, Menopausal Symptoms is further studied across Hot Flashes, Osteoporosis, and Vaginal Atrophy, and Thyroid Disorders is further studied across Hyperthyroidism and Hypothyroidism, enabling fine-grained targeting of clinical indications and patient segments.

Based on technology, the market is studied across Chemical Synthesis and Recombinant DNA Technology; the Chemical Synthesis pathway is further studied across Liquid-Phase Synthesis and Solid-Phase Synthesis while the Recombinant DNA Technology pathway is further studied across Bacterial Expression Systems, Mammalian Cell Expression Systems, and Yeast Expression Systems, highlighting trade-offs between yield, post-translational modification fidelity, and cost of goods. Based on end user, the market is studied across Clinics, Homecare Settings, Hospitals, Online Pharmacies, and Retail Pharmacies; within that classification the Clinics category is further disaggregated into General Practice Clinics and Specialty Clinics, Homecare Settings into Nursing Service and Self-Administration, Hospitals into Private Hospitals and Public Hospitals, Online Pharmacies into Over-The-Counter and Prescription-Based models, and Retail Pharmacies into Chain Pharmacies and Independent Pharmacies, which clarifies distribution pathways, reimbursement touchpoints, and patient access considerations.

These segmentation lenses collectively enable stakeholders to prioritize investments, design differentiated clinical evidence strategies, and align manufacturing footprints with the specific demands of each therapeutic and channel combination.

Region-specific implications for regulation, manufacturing capacity, and commercial engagement across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics present distinctive regulatory, manufacturing, and commercial contours that influence strategic choices. In the Americas, advanced clinical ecosystems and strong insulin and contraceptive demand coexist with concentrated manufacturing clusters that prioritize biologics scale-up and advanced formulation capabilities. In Europe, Middle East & Africa, regulators increasingly harmonize biosimilar pathways while healthcare systems emphasize cost containment and access, prompting manufacturers to refine value dossiers and engage more deeply with regional health technology assessment processes. In Asia-Pacific, rapid adoption of recombinant technologies and growing capacity in both established and emerging manufacturing hubs are complemented by expanding private and public healthcare spending, creating competitive pressure and collaborative opportunities for contract manufacturing and local partnerships.

Across these regions, differences in reimbursement paradigms, clinical practice patterns, and supply chain resilience require tailored market entry and growth strategies. Regulatory alignment initiatives and regional trade agreements can create avenues for streamlined approvals and cross-border clinical collaboration, but local manufacturing capabilities and distribution networks remain decisive factors for ensuring timely patient access. Consequently, companies that develop region-specific pathways for evidence generation, regulatory engagement, and channel management are better positioned to convert scientific strengths into sustained commercial performance.

Critical competitive dynamics and partnership strategies that determine capacity, technological differentiation, and commercialization effectiveness in the hormone therapeutics sector

Competitive dynamics in synthetic hormones are shaped by a mix of multinational pharmaceutical corporations, specialized biotechnology firms, contract development and manufacturing organizations, and emerging innovators focused on novel delivery platforms. Leading biologics developers have leveraged investments in recombinant technologies and advanced cell expression systems to extend their presence across insulin analogs and growth hormone therapies, while traditional small-molecule manufacturers continue to refine chemical synthesis routes for peptide and steroid-based hormones.

Strategic collaboration between originators and contract manufacturers has intensified as companies seek modular capacity and flexible supply arrangements. Partnerships with technology providers that specialize in high-yield bacterial and mammalian expression systems, as well as firms that offer advanced formulation and device integration, are increasingly important for accelerating time to clinic and ensuring scalable production. Mergers and acquisitions activity concentrates on filling capability gaps, securing geographic manufacturing footprint, and acquiring differentiated delivery technologies that enhance patient adherence. The competitive landscape rewards organizations that combine scientific differentiation with operational excellence, evidenced by investments in regulatory compliance, quality management systems, and integrated data platforms that support lifecycle evidence generation.

Targeted and practical recommendations for leaders to strengthen resilience, accelerate commercialization, and align development with evolving care delivery models

Industry leaders should pursue a set of prioritized, actionable measures to strengthen resilience and accelerate value creation. First, align R&D priorities with delivery and manufacturing feasibility by selecting development pathways that balance clinical differentiation with cost-to-serve considerations, and by validating scalable production routes early in the lifecycle. Second, diversify sourcing across raw materials and intermediates and build contingency supply agreements or dual-sourcing arrangements to reduce vulnerability to policy-driven tariffs and logistic bottlenecks. Third, invest in regulatory strategy and post-market evidence generation to address biosimilarity concerns, long-term safety questions, and regional reimbursement requirements. These efforts should include proactive engagement with regulators and health technology assessment bodies to streamline market access.

Fourth, redesign commercial models to reflect evolving patient pathways by supporting homecare and self-administration programs, enabling remote monitoring, and leveraging prescription-based online channels to enhance adherence and reach underserved populations. Fifth, pursue strategic collaborations with contract manufacturers and technology partners to access specialized expression systems, formulation expertise, and device integration capabilities without the need for heavy capital outlays. Lastly, embed advanced analytics and quality-by-design principles across development and manufacturing to improve yield, reduce batch failures, and accelerate time-to-clinic. Executed together, these actions will enable companies to mitigate near-term disruptions while building differentiated, sustainable advantage.

Rigorous multi-method methodology combining primary stakeholder engagement, regulatory and patent analysis, and triangulated secondary evidence to ensure robust insights

The research methodology combines primary and secondary approaches to ensure robust, triangulated insights. Primary research encompassed structured interviews and in-depth discussions with stakeholders across the value chain including R&D leads, manufacturing heads, regulatory affairs specialists, commercial executives, clinical investigators, and payers. This qualitative input was complemented by systematic document analysis of regulatory guidance, clinical trial registries, patent landscapes, and publicly disclosed regulatory submissions to understand recent precedent and evidentiary expectations.

Secondary research drew on peer-reviewed literature, conference proceedings, technology white papers, and company disclosures to map technological trajectories and historical performance trends. Data synthesis followed a transparent triangulation process that reconciled divergent perspectives and tested hypotheses against multiple independent sources. Where appropriate, scenario analyses were used to examine the operational implications of supply chain disruptions, tariff changes, and regulatory shifts. Quality controls included cross-validation of interview findings, methodological audits, and review by domain experts to ensure the integrity and relevance of the conclusions presented.

Concise and forward-looking conclusion synthesizing strategic imperatives, operational risks, and opportunity pathways for synthetic hormone stakeholders

In summary, the synthetic hormones sector is at an inflection point where scientific capability, regulatory evolution, and shifting care models intersect. Advances in recombinant DNA technologies and improved chemical synthesis routes are unlocking new therapeutic options and enabling more patient-centric delivery modalities, yet these opportunities are counterbalanced by complex manufacturing requirements, evolving regulatory expectations, and policy-induced supply chain pressures. Stakeholders that proactively integrate evidence generation, regulatory engagement, and supply chain resilience into their strategic planning will be better equipped to translate innovation into scalable, cost-effective patient solutions.

Moving forward, success will depend on pragmatic alignment across R&D, manufacturing, and commercial functions, coupled with targeted partnerships that bring specialized capabilities without excessive capital commitments. By emphasizing flexible sourcing, robust quality systems, and patient-oriented distribution channels, organizations can navigate near-term disruptions while positioning themselves to capture long-term clinical and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in personalized hormone replacement therapies using biosynthetic estradiol and testosterone analogues
  • 5.2. Integration of AI-driven molecular design to accelerate novel synthetic peptide hormone discovery
  • 5.3. Regulatory approvals driving adoption of long-acting depot formulations for synthetic GnRH analogues
  • 5.4. Rising investment in plant-based biosynthetic routes for sustainable progesterone production
  • 5.5. Expansion of synthetic insulin analogues with ultra-rapid-acting profiles for precise glycemic control
  • 5.6. Development of oral synthetic peptide hormones through permeability enhancers and nanocarriers
  • 5.7. Growth of telehealth prescribing platforms boosting demand for at-home hormone therapy kits
  • 5.8. Strategic partnerships between pharma and biotech to scale up chemoenzymatic hormone synthesis
  • 5.9. Advancements in continuous subcutaneous delivery systems for synthetic human growth hormone
  • 5.10. Market shift towards lab-grown microbial fermentation routes for cost-effective hGH production

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Synthetic Hormones Market, by Hormone Class

  • 8.1. Estrogen
  • 8.2. Insulin
  • 8.3. Thyroid

9. Synthetic Hormones Market, by Application

  • 9.1. Contraception
    • 9.1.1. Combined Oral Contraceptive
    • 9.1.2. Progestin Only Contraceptive
  • 9.2. Diabetes
  • 9.3. Growth Hormone Deficiency
    • 9.3.1. Adult GHD
    • 9.3.2. Pediatric GHD
  • 9.4. Menopausal Symptoms
    • 9.4.1. Hot Flashes
    • 9.4.2. Osteoporosis
    • 9.4.3. Vaginal Atrophy
  • 9.5. Thyroid Disorders
    • 9.5.1. Hyperthyroidism
    • 9.5.2. Hypothyroidism

10. Synthetic Hormones Market, by Technology

  • 10.1. Chemical Synthesis
    • 10.1.1. Liquid-Phase Synthesis
    • 10.1.2. Solid-Phase Synthesis
  • 10.2. Recombinant Dna Technology
    • 10.2.1. Bacterial Expression Systems
    • 10.2.2. Mammalian Cell Expression Systems
    • 10.2.3. Yeast Expression Systems

11. Synthetic Hormones Market, by End User

  • 11.1. Clinics
    • 11.1.1. General Practice Clinics
    • 11.1.2. Specialty Clinics
  • 11.2. Homecare Settings
    • 11.2.1. Nursing Service
    • 11.2.2. Self-Administration
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals
  • 11.4. Online Pharmacies
    • 11.4.1. Over-The-Counter
    • 11.4.2. Prescription-Based
  • 11.5. Retail Pharmacies
    • 11.5.1. Chain Pharmacies
    • 11.5.2. Independent Pharmacies

12. Synthetic Hormones Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Synthetic Hormones Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Synthetic Hormones Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Pfizer Inc.
    • 15.3.2. Johnson & Johnson
    • 15.3.3. AbbVie Inc.
    • 15.3.4. Bristol Myers Squibb Company
    • 15.3.5. Sanofi SA
    • 15.3.6. AstraZeneca PLC
    • 15.3.7. Novo Nordisk A/S
    • 15.3.8. Merck & Co., Inc.
    • 15.3.9. Teva Pharmaceutical Industries Ltd.
    • 15.3.10. Ferring B.V.
    • 15.3.11. Endo Pharmaceuticals Inc.
    • 15.3.12. Lupin Pharmaceuticals Inc.
    • 15.3.13. IBSA Institute Biochimique SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL SYNTHETIC HORMONES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. SYNTHETIC HORMONES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. SYNTHETIC HORMONES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SYNTHETIC HORMONES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SYNTHETIC HORMONES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SYNTHETIC HORMONES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2